Docusign Inc vs Guardant Health Inc. Common Stock — how do they compare? Docusign Inc trades at $70.3 (market cap $13.35B), while Guardant Health Inc. Common Stock trades at $167.29 (market cap $22.22B). The key difference: Guardant Health Inc. Common Stock is the larger of the two by market cap, and Docusign Inc is more actively traded (3,158,858 versus 1,589,453). Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Guardant Health Inc. Common Stock for 1 Days on average.
| DOCU | GH | |
|---|---|---|
Market Cap | $13.35B | $22.22B |
Volume | 3,158,858 | 1,589,453 |
Sector | Technology | Health |
52-Week High | $73.14 | $187.22 |
52-Week Low | $41.75 | $61.73 |
Typical Hold Time | 71 Days | 1 Days |
Enterprise Value | $12.76B | $22.86B |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $70.08, up 1.71% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.98 billion in 2025, with net income surging to $1.07 billion, though cash flow turned negative. Recent news highlights AI integration in contract processing and leadership in workflow software.
Outlook remains positive with continued earnings momentum and AI-driven growth, but risks include insider selling and competitive pressures. The stock offers growth potential but requires monitoring of cash flow trends and market saturation in e-signature adoption.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →